A nonhuman primate model with Alzheimer's disease-like pathology induced by hippocampal overexpression of human tau.
A nonhuman primate model with Alzheimer's disease-like pathology induced by hippocampal overexpression of human tau.
复制标题
DOI:
10.1186/s13195-024-01392-0
复制
发表时间:
2024-01-27
期刊:
影响因子:
--
通讯作者:
中科院分区:
文献类型:
--
作者:
Alzheimer’s disease (AD) is one of the most burdening diseases of the century with no disease-modifying treatment at this time. Nonhuman primates (NHPs) share genetic, anatomical, and physiological similarities with humans, making them ideal model animals for investigating the pathogenesis of AD and potential therapies. However, the use of NHPs in AD research has been hindered by the paucity of AD monkey models due to their long generation time, ethical considerations, and technical challenges in genetically modifying monkeys. Here, we developed an AD-like NHP model by overexpressing human tau in the bilateral hippocampi of adult rhesus macaque monkeys. We evaluated the pathological features of these monkeys with immunostaining, Nissl staining, cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI), positron emission tomography (PET), and behavioural tests. We demonstrated that after hippocampal overexpression of tau protein, these monkeys displayed multiple pathological features of AD, including 3-repeat (3R)/4-repeat (4R) tau accumulation, tau hyperphosphorylation, tau propagation, neuronal loss, hippocampal atrophy, neuroinflammation, Aβ clearance deficits, blood vessel damage, and cognitive decline. More interestingly, the accumulation of both 3R and 4R tau is specific to NHPs but not found in adult rodents. This work establishes a tau-induced AD-like NHP model with many key pathological and behavioural features of AD. In addition, our model may potentially become one of the AD NHP models adopted by researchers worldwide since it can be generated within 2 ~ 3 months through a single injection of AAVs into the monkey brains. Hence, our model NHPs may facilitate mechanistic studies and therapeutic treatments for AD. The online version contains supplementary material available at 10.1186/s13195-024-01392-0.
登录
查看更多内容
DOI:
10.1002/alz.12318
发表时间:
2021-06
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
作者:
Beckman D;Chakrabarty P;Ott S;Dao A;Zhou E;Janssen WG;Donis-Cox K;Muller S;Kordower JH;Morrison JH
通讯作者:
Morrison JH
影响因子:
12.7
作者:
Ashton NJ;Pascoal TA;Karikari TK;Benedet AL;Lantero-Rodriguez J;Brinkmalm G;Snellman A;Schöll M;Troakes C;Hye A;Gauthier S;Vanmechelen E;Zetterberg H;Rosa-Neto P;Blennow K
通讯作者:
Blennow K
DOI:
10.1002/alz.12325
发表时间:
2021-06
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
作者:
Datta D;Leslie SN;Wang M;Morozov YM;Yang S;Mentone S;Zeiss C;Duque A;Rakic P;Horvath TL;van Dyck CH;Nairn AC;Arnsten AFT
通讯作者:
Arnsten AFT
影响因子:
4.3
作者:
Buchman AS;Bennett DA
通讯作者:
Bennett DA
影响因子:
4.6
作者:
Criscuolo C;Fontebasso V;Middei S;Stazi M;Ammassari-Teule M;Yan SS;Origlia N
通讯作者:
Origlia N